Applicant, as named in the Orange Book
Amgen Inc
Amgen Inc · Nasdaq: AMGN
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Otezla on 29 Nov 2034. 3 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Otezla NDA 205437 · 3 strengths apremilast | 29 Nov 2034 patent |
| Lumakras NDA 214665 · 3 strengths sotorasib | 15 Sep 2040 patent, carve-out possible |
| Otezla Xr NDA 210745 apremilast | 27 May 2042 patent |
Recent events
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 20 Jan 2027Detected 24 Oct 2026
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 19 Jan 2027Detected 24 Oct 2026
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 20 Jan 2027Detected 24 Oct 2026
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 19 Jan 2027Detected 24 Oct 2026
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 20 Jan 2027Detected 24 Oct 2026
- Otezla · Exclusivity expires within 90 days PEDExclusivity expires 19 Jan 2027Detected 24 Oct 2026
- Corlanor · Enters 12-month window basis: patentListed date 12 Jun 2027Detected 24 Oct 2026
- Corlanor · Enters 12-month window basis: patentListed date 12 Jun 2027Detected 24 Oct 2026
- Otezla Xr · Exclusivity expires within 90 days PEDExclusivity expires 20 Jan 2027Detected 24 Oct 2026
- Otezla Xr · Exclusivity expires within 90 days PEDExclusivity expires 19 Jan 2027Detected 24 Oct 2026
- Corlanor · Enters 12-month window basis: patentListed date 12 Dec 2026Detected 24 Oct 2026